< Go to adacap.com| This site is for health care professionals only

Prostate Cancer

  • Disease Education
  • MOA Resources
  • Clinical Trials

Chapter 1: Why Is Precision Medicine Complicated in Advanced Prostate Cancer?

Joe O'Sullivan, MD, FRCPI, FFRRCSI, FRCR

Chapter 2: How Can Phenotypic Biomarkers Increase the Use of Precision Medicine in Advanced Prostate Cancer?

Ken Herrmann, MD, MBA

Chapter 3: How Does PSMA Provide a Tailored Approach in Advanced Prostate Cancer?

Enrique Grande, MD, PhD

PSMA Downloadable Monograph

This monograph offers a detailed review of the possible role of phenotypic precision medicine in advanced prostate cancer.

View Monograph

PSMA Flashcard

This front-and-back flash card displays a quick snapshot of the key points on how phenotypic biomarkers can simplify the approach to precision medicine in advanced prostate cancer.

View Flashcard
PSMA Expression infographic

Expression of PSMA on Prostate Tumor Cells

Infographic depicting the potential utility of prostate-specific membrane antigen (PSMA) for targeted radioligand imaging and therapy.

View Infographic

PSMA Expression and Relevance in Advanced Prostate Cancer

Prostate-specific membrane antigen (PSMA), a biomarker highly expressed on prostate cancer cells, is a potential target under investigation for diagnostic imaging and potential therapy.

PSMA Expression infographic

Pocket PSMA: Explore the Science of Targeted Radioligands

 

View Infographic
Prostate Cancer Patient Journey

Prostate Cancer Patient Journey

Infographic depicting the various potential treatment options for a hypothetic patient with advanced prostate cancer. Note, potential options may not be approved by regulatory authorities in all countries/regions

View Infographic
What is Radioligand Imaging and Therapy in Cancer?

What Is Radioligand Imaging and Therapy in Cancer?

 

Click Here to Learn More About PSMA and Phenotypic Precision Medicine

[177Lu]Lu-PSMA-617 Mechanism of Action

Explore the mechanism of action of targeted radioligand therapy (RLT) [177Lu]Lu-PSMA-617 (177Lu-PSMA-617).

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. MOA data are based on in vitro/in vivo data. Clinical benefit is unknown.

Reimagining Prostate Cancer With Targeted Radioligands

An overview of the AAA pipeline for targeted radioligand therapy and precision imaging

Explore Clinical Trials

PSMAfore

PSMA-Targeted Therapy

A Phase III, open-label, multicenter, randomized study comparing [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) vs a change of androgen receptor-directed therapy in the treatment of taxane-naïve men with progressive metastatic castration-resistant prostate cancer

PSMAddition

PSMA-Targeted Therapy

An open-label, randomized, Phase III study comparing [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) in combination with standard of care, vs standard of care alone, in adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC)

NeoRay

GRPR-Targeted Therapy

A Phase I/IIa, open-label, multicenter study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry, and antitumor activity of [177Lu]Lu-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)

GuidePath

PMSA-Targeted Imaging

Phase III study for evaluation of the diagnostic performance of [18F]CTT1057 PET imaging in patients with prostate cancer with rising PSA levels (biochemical recurrence [BCR])

GuideView

PMSA-Targeted Imaging

Phase II/III study for evaluation of the diagnostic performance of [18F]CTT1057 PET imaging for the detection of PSMA-positive tumors using histopathology as a standard of truth

VISION Infographic

Infographic depicting the main results from the VISION phase 3 study comparing 177Lu-PSMA-617 added to standard of care, vs standard of care alone, in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Explore Compounds

[177Lu]Lu-PSMA-617

 

Investigational PSMA-targeted radioligand therapy

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. MOA data are based on in vitro/in vivo data. Clinical benefit is unknown.

Explore Pipeline Explore Clinical Trials